Genetic Testing for Antidepressants: What Your DNA Can and Cannot Tell You

Depression is one of the most common mental health conditions worldwide, and antidepressants are among the most prescribed medications. Yet finding the right antidepressant often involves trial and error — a process that can take weeks or months, during which patients may experience side effects, inadequate relief, or both.

Pharmacogenomics offers one piece of this puzzle. By analyzing genetic variants in drug-metabolizing enzymes, genetic testing for antidepressants can identify whether your body processes certain medications faster or slower than expected — information that may help your prescriber choose a starting dose or consider alternative medications.

This article explains what genetic testing for antidepressants can and cannot tell you about depression treatment, which genes are most relevant, and how to interpret results in the context of psychiatric care. For a broader overview of pharmacogenomics from consumer DNA data, see our complete guide to pharmacogenomics from raw DNA data.

The Two Key Genes: CYP2D6 and CYP2C19

The majority of CPIC-guideline psychiatric drug-gene interactions involve two pharmacogenes:

• CYP2D6 — Metabolizes many antidepressants including fluoxetine (Prozac), paroxetine (Paxil), fluvoxamine (Luvox), venlafaxine (Effexor), nortriptyline, amitriptyline, and desipramine. Also metabolizes antipsychotics and atomoxetine (ADHD). See our full list of CYP2D6-affected antidepressants.
• CYP2C19 — The primary metabolic pathway for escitalopram (Lexapro), sertraline (Zoloft), citalopram (Celexa), and several tricyclic antidepressants including amitriptyline, clomipramine, and imipramine. See our CYP2C19 and SSRI metabolism guide for a deeper look at which SSRIs are most affected.

Your metabolizer status for each gene is determined by the combination of genetic variants you carry. This status predicts your enzyme activity level: ultrarapid, normal, intermediate, or poor.

What Pharmacogenomics CAN Tell You

Pharmacogenomic testing for depression can provide clinically useful information in several areas:

• Drug metabolism rate: Whether your body is likely to process a specific antidepressant faster or slower than the population average, which affects plasma drug levels at standard doses.
• Side-effect risk context: CYP2C19 poor metabolizers taking escitalopram, for example, may have higher drug exposure, which CPIC guidelines associate with increased risk of dose-dependent side effects.
• Dose adjustment guidance: CPIC guidelines provide specific recommendations — for example, considering a 50% dose reduction for escitalopram in CYP2C19 poor metabolizers, or avoiding codeine in CYP2D6 ultrarapid metabolizers.
• Medication selection context: If your genotype flags multiple medications in one drug class, your prescriber may consider alternatives in a different class or metabolic pathway.

What Pharmacogenomics CANNOT Tell You

It is equally important to understand the limitations:

• It cannot predict antidepressant efficacy. Pharmacogenomics tells you how your body processes a drug — not whether it will reduce your symptoms. Depression involves complex neurobiology that extends far beyond drug metabolism.
• It cannot diagnose depression or anxiety. This is a metabolism test, not a diagnostic test.
• It does not account for all factors affecting drug response. Age, weight, liver function, kidney function, other medications, diet, and adherence all influence how you respond to antidepressants.
• It covers specific genes, not the whole genome. CYP2D6 and CYP2C19 are the best-studied pharmacogenes for antidepressants, but other genes and pathways may also play a role that current testing does not capture.

How CPIC Guidelines Apply to Antidepressants

The Clinical Pharmacogenetics Implementation Consortium (CPIC) has published Level A guidelines — the strongest evidence category — for several antidepressant-gene pairs. These guidelines do not tell prescribers which antidepressant to choose for a given patient. Instead, they provide evidence-based recommendations for dose adjustments or alternative drug selection when a patient's genotype is known.

For example, the CPIC SSRI guideline (Hicks et al., 2015; PMID: 25974703) covers escitalopram, citalopram, sertraline, paroxetine, and fluvoxamine. For CYP2C19 poor metabolizers taking escitalopram, the guideline recommends considering a 50% dose reduction or selecting an alternative SSRI. For CYP2D6 poor metabolizers taking paroxetine, it recommends selecting an alternative drug not predominantly metabolized by CYP2D6.

These are prescriber-level decisions. Pharmacogenomic results provide context — not directives. Learn more about how pharmacogenomic testing works.

Using 23andMe or AncestryDNA Data

If you have taken a consumer DNA test, your raw data file likely contains the key CYP2D6 and CYP2C19 variants needed for pharmacogenomic analysis. DecodeMyBio's Psychiatric Medication Report analyzes these variants and maps them to CPIC guidelines for antidepressants, ADHD medications, and antipsychotics.

Consumer arrays cannot detect gene deletions or duplications (relevant to CYP2D6 ultrarapid and poor metabolizer classification). Results from consumer data are informational and should be discussed with your prescriber. See our limitations page for details, or learn what to do with your 23andMe raw data.

How This Differs from GeneSight

Services like GeneSight offer clinician-ordered pharmacogenomic testing focused on psychiatric medications. GeneSight uses a proprietary combinatorial algorithm, requires a prescription, and typically costs ~$330 without insurance.

DecodeMyBio uses DNA data you already have, maps results to published CPIC and DPWG guidelines (not a proprietary algorithm), and costs $59 with no prescription required. See our detailed comparison of pharmacogenomics testing options.